Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

recruiting150%
terminated150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_2

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

NCT06475326
terminatedphase_2

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

NCT03422523

Clinical Trials (2)

Showing 2 of 2 trials
NCT06475326Phase 2

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Recruiting
NCT03422523Phase 2

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2